Drug Approval | March 31, 2026
Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
It promises fewer injections for vision loss patients
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Subscribe To Our Newsletter & Stay Updated
